Triton completes the acquisition of Bormioli Rocco’s pharma business

Report this content

Milan/Fidenza (Italy), 30 November 2017 - Funds advised by Triton ("Triton") have successfully completed the acquisition of Bormioli Rocco’s pharma business (“Bormioli Pharma”), a leading pharma primary packaging manufacturer from Vision Capital. Terms of the acquisition were not disclosed.

"We want to support the management and employees of the Bormioli Pharma business by investing in and supporting the growth and development of the company. We will contribute our strategic insights from the industry and region. We look forward to working together with the management team and the Board of Directors in building a stronger company", said Peder Prahl, Director of the General Partner for the Triton funds.

"Bormioli Pharma, as a market leader, has been continuously building its current presence over the last years. This transaction is an important milestone, enabling the company to continue with its strategic efforts", said Riccardo Garrè, Executive Chairman of Bormioli Rocco.

“Bormioli Pharma is a great company in an interesting industry segment with strong fundamentals and we are looking forward to supporting its further growth and development in the coming years”, added Fabrizio Gualdi, Investment Advisory Professional and Advisor to the Triton Funds.

About Bormioli Pharma
Established in 1825, Bormioli Rocco’s pharma business is a leading Italian pharma primary packaging manufacturer. Bormioli Rocco Pharma has 5 manufacturing plants and sells its products to more than 90 countries worldwide. Bormioli Rocco Pharma employs over 900 people and has an annual turnover of € 217 million.

About Triton
The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe, focusing on businesses in the Industrial, Business Services and Consumer/Health sectors.

Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth. The 34 companies currently in Triton's portfolio have combined sales of around €15 billion and around 92,000 employees.

The Triton funds are advised by dedicated teams of professionals based in Germany, Sweden, Norway, Finland, Denmark, Italy, the United Kingdom, the United States, China, Luxembourg and Jersey.

For further information: www.triton-partners.com

Triton
Marcus Brans                                                 
Phone: +49 69 921 02204  

Bormioli Rocco
Elisa Lavagna, Brunswick Group
+39 02 9288 6200

Vision Capital
Alison Kay/Miranda Ward, Brunswick Group
Phone: +44(0) 20 7404 5959

Quick facts

Bormioli Rocco Pharma has 5 manufacturing plants and sells its products to more than 90 countries worldwide
Tweet this

Quotes

Bormioli Pharma is a great company in an interesting industry segment with strong fundamentals and we are looking forward to supporting its further growth and development in the coming years
Fabrizio Gualdi, Investment Advisory Professional and Advisor to the Triton Funds